New horizons in lung cancer management through ATR/CHK1 pathway modulation.

Publication Type:
Journal Article
Future Med Chem, 2023
Issue Date:
Filename Description Size
ATR:CHK1_Lung Cancer_fmc-2023-0164.pdfAccepted version277.53 kB
Adobe PDF
Full metadata record
Lung cancer is the leading cause of cancer-related deaths worldwide. Molecular profiling has contributed to a new classification of lung cancer, driving advancements in research and therapy. The ataxia telangiectasia and rad3/checkpoint kinase 1 (ATR/CHK1) pathway plays a crucial role in maintaining genomic stability, and its activation has been linked to the development of lung cancer, drug resistance and poor prognosis. Clinical and preclinical studies have demonstrated promising results in targeting this pathway. ATR and CHK1 are proteins that collaborate to repair DNA damage caused by radiation or chemotherapy. ATR/CHK1 inhibitors are currently under investigation in preclinical and clinical trials. This article explores the ATR/CHK1 pathway and its potential for treating lung cancer.
Please use this identifier to cite or link to this item: